SR One Capital Management — Full Portfolio

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

RWReid Waldman(Chief Executive Officer and Board Member)inTDTim Durso(Chief Technical Officer)inDCDominic Carrano(Chief Financial Officer and Treasurer)inMNMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Board seatKPKatarina Pance· per SEC Form D

Co-investorsLOLongitude CapitalCOConnecticut InnovationsLILifeSci Venture PartnersOUOUP (Osage University Partners)ABabrdn plcINInvus

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LOLEON O. MOULDER, JR.(Director)LMLonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HMHUA MU(Executive Officer, Director)in

BoardPGPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Board seatJNJake Nunn· per SEC Form D

Co-investorsDEDelos CapitalLOLongitude CapitalNENew Enterprise Associates (NEA)NONorwest Venture PartnersPIPivotal Life SciencesQUQuan Capital+3 more

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

MBMartin Babler(President, Chief Executive Officer and Chairman of the Board)inMBMark Bradley(Chief Development Officer)inKBKolbot By(SVP, Head of Technical Operations)inJDJack Danilkowicz(Chief Commercial Officer)inJDJörn Drappa(Chief Medical Officer)inDMDavid M Goldstein(Chief Scientific Officer)in

Co-investorsFOForesite CapitalHBHBM Healthcare InvestmentsHBHBM PartnersNENextech InvestOROrbiMedSASamsara BioCapital+3 more

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

LBLyn Baranowski(CEO)in

Co-investorsANAndera PartnersCACatalio Capital Management, LPF-F-Prime CapitalINInVivium CapitalNONorwest Venture PartnersPIPivotal Life Sciences+9 more

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

GWGregory Winter(Director)inKLKEVIN LEE(Executive Officer, Director)inNCNIGEL CROCKETT(Executive Officer)inNKNICHOLAS KEEN(Executive Officer)SASANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)

Co-investorsAHAhren Innovation CapitalASAstellas Venture Management LLCCACambridge Innovation CapitalDEDementia Discovery FundLOLongwood FundRIRidgeback Capital+4 more

Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.

BiotechMedical DevicesSolana Beach, US

PSPratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)SJSean Jeffries, Ph.D.(Executive Officer)

BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)

Co-investorsAVAvoro Capital AdvisorsQUQuan CapitalRARA CapitalWEWellington ManagementWEWestRiver GroupQUQuan Venture

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

JHJustin Hanes(Director)inKPKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTBTodd Bazemore(Executive Officer)inMIMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Co-investorsLOLongitude CapitalWEWellington ManagementYSYsios CapitalATAtlas VentureLULux CapitalRARA Capital+1 more

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)inAGAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)OLOlivier Litzka(Director)in

Co-investorsANAndera PartnersHBHBM Healthcare InvestmentsHBHBM PartnersSASamsara BioCapitalYSYsios CapitalADAdams Street Partners+3 more

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

PHPaul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPJPaul J. Hastings(Chief Executive Officer)in

BoardMichael Dybbs(Director)JCJill Carroll(Director)in

Co-investorsNENew Enterprise Associates (NEA)RARA CapitalSASamsara BioCapitalAMAmgen VenturesLOLogosNONorwest Venture Partners+1 more

Oruka is a biopharmaceutical company developing monoclonal antibody therapies aimed at treating plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions with fewer annual doses.

BiotechHealthtech

Lawrence Klein(Chief Executive Officer and Director)in

Progyny provides employer-sponsored women's health and family-building benefits, covering preconception, fertility, pregnancy and postpartum, and menopause/midlife care through concierge support, digital tools, and a managed network of specialists.

Digital HealthFemTechHealthtechHR Tech

GBGina Bartasi(Founder)inPeter Anevski(Chief Executive Officer and Director)

Co-investorsAUAurumKLKleiner PerkinsM M VenturesSASavano Capital PartnersUNUnion Grove Venture Partners

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical DevicesSan Diego, US

ZLZhen Li(Co-founder, President & CEO)inRZRui Zhu(Founding Member & Chief Technology Officer)RARob Ackles(Chief People Officer)inRFRyan Fisk(Chief Financial Officer & Chief Business Officer)inRARobert A. MacLeod(Chief Scientific Officer)inCCChristopher Claeboe(Senior Vice President of Operations)in

Co-investorsBABain Capital Life SciencesOROrbiMedLILilly Asia VenturesT.T. Rowe PriceASAscenta CapitalTCTCG Crossover+3 more

Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.

BiotechHealthtechSouth San Francisco, US

KCKathleen Collins(Director)inLKLawrence Kong(Executive Officer)inRPRon Park(President & CEO)inFGFrancine Gregoire(Chief Scientific Officer)inPPPriya Parameswaran(Chief Business Officer)in

BoardJPJayson Punwani(Director)in

Board seatLSLaetitia SchwabMRMatthew R. Patterson· per SEC Form D

Co-investorsBEBEVCPIPivotal Life SciencesABAbingworthOSOsage University Partners

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Board seatRDRajeev Dadoo· per SEC Form D

Co-investorsNENextech InvestOROrbiMedRARA CapitalSOSofinnova Ventures

HealthtechMenlo Park, US

Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)

BoardFCFred Craves(Director)in

Board seatJNJake Nunn· per SEC Form D · $1M raise · filed Dec 2018

Co-investorsAIAisling CapitalBABay City CapitalCACanaan PartnersFOForesite CapitalNENew Enterprise Associates (NEA)FIFidelity Investments+1 more

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

NTNenad Tomasevic(Chief Executive Officer, Founder)

BoardIvan Trifunovich(Director)John Wesley(Director)

Board seatRDRajeev Dadoo· per SEC Form D

Co-investors8V8VCAIAisling CapitalHBHBM Healthcare InvestmentsHBHBM PartnersMIMission Bay CapitalMIMission Biocapital+4 more

BiotechCambridge, US

Rick Lundberg(Executive Officer)GPGeorge P. Vlasuk(Executive Officer, Director)in

BoardJFJean-Francois Formela(Director)inACAlan Crane(Director)inMNMarian Nakada(Director)inBGBrian Gallagher(Director)in

Board seatRDRajeev Dadoo· per SEC Form D · $20.2M raise · filed May 2020

Co-investorsAGage1BRBrace PharmaSASanofi VenturesATAtlas VenturePOPolaris Partners

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

GDGary D Glick(Executive Officer, Director)in

BoardCGCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in

Board seatJCJill Carroll· per SEC Form D

Co-investorsACActivant CapitalASAscenta CapitalBABalderton CapitalCACatalio Capital Management, LPFOForesite CapitalGLGlobal BioAccess Fund+8 more

Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.

BiotechDigital HealthMedical DevicesWaltham, US

James W. Broderick(Executive Officer, Director)Jim Broderick(Co-Founder)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)

Board seatRDRajeev Dadoo· per SEC Form D

Co-investorsMAMatrix Capital ManagementPFPfizer VenturesPFPfizer Venture InvestmentsBIBioHealth Innovation, Inc.TATakeda VenturesVEVertex Ventures HC

Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs.

BiotechHealthtechSan Diego, US

Neil Gibson(Executive Officer)KXKleanthis Xanthopoulos(Executive Officer, Director)

BoardB. Lynne Parshall(Director)Mark G. Foletta(Director)John Maraganore(Director)Douglas E. Williams(Director)

Board seatJNJake Nunn· per SEC Form D · $34.6M raise · filed Dec 2021

Co-investorsFOForesite CapitalNENew Enterprise Associates (NEA)

Endologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures.

HardwareHealthtechMedical DevicesSanta Rosa, US

MVMichael V. Chobotov(Executive Officer)inSLSHARI L. O'QUINN(Executive Officer)inMichael R. Kramer(Executive Officer)KIMBERLEY ELTING(Executive Officer)CHRISTOPHER CHAVEZ(Executive Officer, Director)VKVIVEK K. JAYARAMAN(Executive Officer)in

Board seatJNJake Nunn· per SEC Form D · $10M raise · filed Aug 2015

Co-investors41415 CapitalKAKaiser Permanente VenturesNENew Enterprise Associates (NEA)DEDeerfield Management Company

46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.

Fintech

Tim Clark(Managing Director)

Co-investorsHUHurricane VenturesANAndreessen HorowitzASAscenta CapitalAVAvaana CapitalBOBoxGroupCLClaypond Capital+7 more

Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.

BiotechPalo Alto, US

James Li(Executive Officer, Director)MFMaria Fardis(Executive Officer, Director)in

BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)JCJill Carroll(Director)in

Co-investorsFRFrazier Life SciencesLOLongitude CapitalOROrbiMed

Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsARARCH Venture PartnersWEWestlake Village BioPartners

Ancora Biotech is a privately held biotherapeutics developer overseeing the manufacturing and clinical development of three multi-specific antibodies held in separate spin-offs.

BiotechHealthtech

Co-investorsLILightspeed Venture PartnersSUSutter Hill Ventures

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.

BiotechHealthtechCopenhagen, DK

JJJens Juul Holst(Founder)MRMette Rosenkilde(Founder)in

Co-investorsBRBroadview VenturesNONovo HoldingsVEVersant Ventures

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.

BiotechHealthtechGaithersburg, US

Han Lee(Executive Officer)RERami Elghandour(Executive Officer, Director)in

BoardJCJill Carroll(Director)inABAli Behbahani(Director)inDYDerek Yoon(Director)inTATiba Aynechi(Director)in

Co-investorsLGLG Technology VenturesNENew Enterprise Associates (NEA)QUQuan CapitalSASamsara BioCapitalSISixty Degree CapitalSOSolasta Ventures+5 more

Co-investorsAVAvego BioScience CapitalBIBioGenerator VenturesPEPerot JainRIRiverVest Venture PartnersRORoche Venture Fund

Biotech

Co-investorsKUKurma PartnersSOSofinnova PartnersJOJohnson & Johnson Innovation – JJDCM M VenturesEQEQT Life Sciences

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

BiotechSan Diego, US

ACAthena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBSBrian Sun(Executive Officer)in

BoardCarl Gordon(Director)

Co-investorsDEDelos CapitalFOForesite CapitalININCE CapitalLOLongwood FundNENew Enterprise Associates (NEA)OROrbiMed+6 more

Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.

BiotechDeep TechMedical DevicesSan Diego, US

Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))inRWRaymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in

Co-investorsLULumira VenturesRERevelation Partners

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.

AI & Machine LearningBiotechHealthtechLondon

Lakshyaditya Singh Aithani(Executive Officer, Director)

BoardRGRishi Gupta(Director)inNSNihal Sinha(Director)inMMMuzammil Mansuri(Director)inGary Glick(Director)in

Co-investorsF-F-Prime CapitalNENew Enterprise Associates (NEA)OROrbiMedAXAxial VCKHKhosla VenturesNVNVentures

Codify Therapeutics is a discovery-stage biotech developing cancer therapeutics that target abnormal alternative RNA splicing, such as in splicing-factor-mutant leukemias.

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)inSWSimon Ward(Chief Scientific Officer & Founder)in

Co-investorsACAccess BiotechnologyCACanaan PartnersSASanofi VenturesSVSV Health InvestorsBRBritish Business BankJAJanus Henderson Investors

Econic Biosciences is a biotech company developing cancer therapies that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification and tumor evolution.

BiotechDeep TechHealthtechLondon, GB

RLRalph Lindemann(Chief Scientific Officer)Pete Johnson(Head of Medicinal Chemistry)Steven Whittaker(Head of Biology)inAlastair Hamilton(Head of Business Operations & Strategy)in

BoardRodger Novak(Executive Chairman)in

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsHBHBM Healthcare InvestmentsHBHBM PartnersLGLG Technology VenturesNONovartis Venture FundOROrbiMedPOPontifax Venture Capital+4 more

HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.

AI & Machine LearningBiotechHealthtech

BoardBBBruce Booth(Chairman)in

Co-investorsATAtlas VentureB B Capital GroupB4B4 CapitalMRMRL Ventures FundPIPivotal Life SciencesSOSofinnova Partners+2 more

BiotechEast Providence, US

Manny Avila(Executive Officer, Director)inDKDirk Kuyper(Executive Officer, Director)inRobert Rabiner(Executive Officer)

BoardDaniel Omstead(Director)FAFouad Azzam(Director)inRajeev Dadoo(Director)

Co-investorsPAPappas CapitalLILife Sciences Partners

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis.

BiotechMedical Devices

MPMark Pepys(Co-founder; Emeritus Professor of Medicine at UCL)GWGregory Winter(Co-founder; Nobel Laureate)DCDaniel Christ(Co-founder; Professor, Faculty of Medicine, UNSW)

Co-investorsCACambridge Innovation CapitalFRFrazier Life SciencesQIQiming Venture PartnersF-F-Prime Capital

Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers.

BiotechHealthtech

Co-investorsOROrbiMed

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsPFPfizer Venture InvestmentsRORoche Venture FundRORosetta Capital Ltd.SOSofinnova Partners

Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesDEDementia Discovery FundGVGV (Google Ventures)LILightstone Ventures+4 more

Nomic is an AI platform for architecture, engineering, and construction (AEC) teams that orchestrates agents across drawings, specs, submittals, RFIs, and building codes to automate coordination and review work.

AI & Machine LearningConstruction TechEnterprise Software

BDBrandon Duderstadt(Founder)in

Co-investorsBEBetaworksCOCoatue ManagementCOContrary202048 VenturesDYDynamk CapitalLULux Capital

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

BiotechCambridge, US

JVJo Viney(Executive Officer)RKRahul Kakkar(Executive Officer, Director)inACAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Co-investorsACAccess BiotechnologyJDJDRF T1D FundMIMission BiocapitalRARA CapitalPOPolaris PartnersVEVersant Ventures

Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.

Biotech

Co-investorsRARA CapitalVIVida Ventures

BiotechSouth San Francisco, US

MBMARTIN BABLER(Executive Officer, Director)in

BoardPTPETER THOMPSON(Director)inSASRINIVAS AKKARAJU(Director)MDMICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)

Co-investorsACAccess BiotechnologyMIMission BiocapitalSOSofinnova VenturesMIMission Bay CapitalNENew Leaf Venture PartnersOROrbiMed+1 more

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

PSPete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDMDavid Mantusin

Co-investorsADAdjuvant CapitalASAsahi Kasei Corporate Venture CapitalDEDementia Discovery FundF-F-Prime CapitalJEJeito CapitalLOLongwood Fund+4 more

Rezo maps disease networks to find insights into disease biology for drug discovery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

NKNevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNBNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)GSGeorge Scangos(Co-Founder)Kevan Shokat(Co-Founder)

Co-investorsANAndreessen HorowitzNONorwest Venture PartnersHAHAWKTAILVAValkyrie Ventures Management, LlcARARCH Venture PartnersSVSV Angel

Co-investorsLILifeforce CapitalPFPfizer Venture InvestmentsDIDigitalis VenturesLILightstone VenturesMOMorgenthalerRORoche Venture Fund

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

ARAaron Ring(Executive Officer, Director)inBMBeatrice McQueen(Chief Operating Officer)inSRSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)HUHirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsCOConnecticut InnovationsPFPfizer Venture InvestmentsAXAxial VCBIBiotechnology Value FundRORock Springs CapitalSASamsara BioCapital

Telios Pharma is a clinical-stage biopharmaceutical company developing first-in-class topical and oral BTK-inhibitor drugs targeting mast-cell-mediated inflammation, including TL-925 for dry eye disease.

Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.

BiotechHealthtechCambridge, US

HTHui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)MMMagdalene Moran(Chief Executive Officer)

BoardKKKarin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)

Co-investorsMRMRL Ventures FundTHThe Column Group

Co-investorsVIVivo CapitalRERemiges Ventures, Inc.

Co-investorsFOForesite CapitalLALAVLILilly Asia VenturesNENextech InvestSVSv Tech Ventures, Inc.HBHBM Partners

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOROrbiMedQUQuan CapitalRARA CapitalSASanofi VenturesJAJanus Henderson InvestorsNONovo Holdings+3 more

Xap Therapeutics uses genome editing and synthetic biology to engineer a programmable cell-based delivery platform that carries therapeutic payloads such as cytokines, antibodies, and nucleic acids, releasing them upon target recognition.

BiotechDeep TechCambridge, GB